Antares Pharma, Inc. (NASDAQ: ATRS) announced that the FDA has accepted its resubmitted New Drug Application (NDA) for the Complete Response Letter (CRL) of XYOSTED (testosterone enanthate subcutaneous injection). The FDA considered this resubmission a class 2 response and has assigned a PDUFA date of September 29, 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.